{"nctId":"NCT00260832","briefTitle":"Trial of Decitabine in Patients With Acute Myeloid Leukemia","startDateStruct":{"date":"2005-11"},"conditions":["Acute Myeloid Leukemia"],"count":485,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Cytarabine or Supportive Care"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dacogen (decitabine) only"]}],"interventions":[{"name":"Cytarabine or Supportive Care","otherNames":[]},{"name":"Dacogen (decitabine) only","otherNames":["decitabine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Must have diagnosed acute myeloid leukemia.\n2. Must have a life expectancy of at least 12 weeks.\n3. Must sign informed consent.\n\nExclusion Criteria:\n\n1. Must not have acute promyelocytic leukemia (M3 classification)\n2. Must not have any other active systemic malignancies.\n3. Must not have inaspirable bone marrow.\n4. Must not have received previous chemotherapy (except hydroxyurea) for any myeloid disorder.\n5. Must not have chronic respiratory disease that requires continuous oxygen use.\n6. Must not have received any experimental drug within 4 weeks before randomization.\n7. Must not be a candidate for a bone marrow or stem cell transplant within 12 weeks after randomization.\n8. Must not have known HIV.","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival in Patients 65 Years or Older Who Have Newly Diagnosed de Novo or Secondary AML.","description":"The interval from date of randomization to the date of death from any cause or the last date the subject was known to be alive or 5 years whichever occurs first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Incomplete Platelet Recovery (CRp)","description":"Morphologic CR plus CRp rate where Morphologic leukemia-free state defined as less that (\\<) 5 percent (%) blasts in an aspirate sample with marrow spicules and a count of greater than or equal to (\\>=) 200 nucleated cells (there should have been no blasts with Auer rods or persistence of extramedullary disease) plus absolute neutrophil count (ANC) greater than (\\>)1,000 per microliter (/mcL), platelet count of \\>=100,000/mcL, and the participant must have been independent of transfusions for at least 1 week before each assessment. There was no duration requirement for confirmation of this designation and Morphologic CR without the requirement of platelet count \\>=100,000/mcL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":162,"n":237},"commonTop":["Pyrexia","Thrombocytopenia","Anemia","Febrile Neutropenia","Disease Progression"]}}}